# VIASKIN (viaskin) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/viaskin

> VIASKIN (viaskin), sponsored by DBV Technologies S.A. (DBVT): 3 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | VIASKIN (viaskin) |
| Codes |  |
| Sponsor | DBV Technologies S.A. (DBVT) https://sec-api.dev/companies/dbvt/catalysts |
| Indications | peanut-allergic toddlers 1 - 3 years old, peanut-allergic toddlers 1 - 3 years of age |
| Modality |  |
| FDA designations | breakthrough, priority review |

## Timeline

### Jun 2022: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 3. Indication: peanut-allergic toddlers 1 - 3 years of age.
- First seen 2025-04-11, last confirmed 2025-10-28.
- SEC Form 10-Q (accession 0001628280-25-046809): "In June 2022, the Company announced positive topline results from Part B of the Company's EPITOPE phase 3 study assessing the safety and efficacy of the Viaskin Peanut patch for the treatment of peanut-allergic toddlers 1 - 3 years old ("EPITOPE")." https://www.sec.gov/Archives/edgar/data/1613780/000162828025046809/dbvt-20250930.htm
- SEC Form 10-Q (accession 0001613780-25-000016): "In June 2022, the Company announced positive topline results from Part B of the Company's EPITOPE phase 3 study assessing the safety and efficacy of the Viaskin Peanut patch for the treatment of peanut-allergic toddlers 1 - 3 years of age ("EPITOPE")." https://www.sec.gov/Archives/edgar/data/1613780/000161378025000016/dbvt-20250630.htm
- SEC Form 10-Q (accession 0001628280-25-046809): "In June 2022, the Company announced positive topline results from Part B of EPITOPE." https://www.sec.gov/Archives/edgar/data/1613780/000162828025046809/dbvt-20250930.htm
- SEC Form 10-Q (accession 0001613780-25-000016): "In June 2022, the Company announced positive topline results from Part B of EPITOPE." https://www.sec.gov/Archives/edgar/data/1613780/000161378025000016/dbvt-20250630.htm
- SEC Form 10-Q (accession 0001613780-25-000011): "In June 2022, the Company announced positive topline results from Part B of EPITOPE." https://www.sec.gov/Archives/edgar/data/1613780/000161378025000011/dbvt-20250331.htm
- SEC Form 10-K (accession 0001613780-25-000006): "In June 2022, we announced positive topline results from EPITOPE, which enrolled 362 subjects ages 1 to 3 years, of which 244 and 118 were in the active and placebo arms, respectively." https://www.sec.gov/Archives/edgar/data/1613780/000161378025000006/dbvt-20241231.htm
- SEC Form 10-K (accession 0001613780-25-000006): "In June 2022, the Company announced positive topline results from Part B of EPITOPE, which enrolled 362 subjects ages 1-3 years, of which 244 and 118 were in the active and placebo arms respectively." https://www.sec.gov/Archives/edgar/data/1613780/000161378025000006/dbvt-20241231.htm
- SEC Form 10-K (accession 0001613780-25-000006): "In June 2022, we announced positive topline results from Part B of EPITOPE, which enrolled 362 subjects ages 1 to 3 years, of which 244 and 118 were in the active and placebo arms, respectively." https://www.sec.gov/Archives/edgar/data/1613780/000161378025000006/dbvt-20241231.htm

### December 16, 2025: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 3.
- First seen 2026-03-26, last confirmed 2026-03-26.
- SEC Form 10-K (accession 0001628280-26-021504): "On December 16, 2025, the Company announced positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years." https://www.sec.gov/Archives/edgar/data/1613780/000162828026021504/dbvt-20251231.htm
- SEC Form 10-K (accession 0001628280-26-021504): "On December 16, 2025, the Company announced the positive topline results from the VITESSE study and that its primary endpoint was met." https://www.sec.gov/Archives/edgar/data/1613780/000162828026021504/dbvt-20251231.htm
- SEC Form 10-K (accession 0001628280-26-021504): "The Company announced the positive topline results from the VITESSE study on December 16, 2025." https://www.sec.gov/Archives/edgar/data/1613780/000162828026021504/dbvt-20251231.htm

### Q3 2026: NDA/BLA submission

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2026-04-30, last confirmed 2026-07-16.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-306222): "Continued productive engagement with the FDA in support of the BLA for the VIASKIN® Peanut Patch in children aged 4 through 7 years, with submission of the BLA anticipated in the third quarter of 2026" https://www.sec.gov/Archives/edgar/data/1613780/000119312526306222/d156695dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-197921): "In the first quarter of 2026, the Company started to execute its plan for growth, building on the key events from 2025, including the receipt of regulatory alignment with the U.S. Food and Drug Administration in the first quarter of 2025 regarding the safety data requirements and positive phase 3 clinical results in the fourth quarter, that will both support the planned BLA submission for the VIASKIN® Peanut Patch in children aged 4 to 7 years in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1613780/000119312526197921/d132063dex991.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/viaskin.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "VIASKIN (viaskin) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/viaskin

```bibtex
@misc{secapidev_pdufa_viaskin_20261116,
  title        = {VIASKIN (viaskin) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/viaskin}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_viaskin_20261116","title":"VIASKIN (viaskin) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/viaskin","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
